Photocure (PHO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Photocure (PHO) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr26.43 Million ≈ $2.78 Million USD) by net assets (Nkr486.60 Million ≈ $51.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Photocure - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Photocure's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHO liabilities breakdown for a breakdown of total debt and financial obligations.
Photocure Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Photocure ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
0.013x |
|
VAA Vista Alegre Atlantis SGPS SA
LS:VAF
|
0.066x |
|
Dynacor Gold Mines Inc.
TO:DNG
|
0.011x |
|
Ador Welding Limited
NSE:ADORWELD
|
0.013x |
|
Panion & BF Biotech Inc
TW:1760
|
0.039x |
|
Solid FAB
ST:SFAB
|
0.072x |
|
PIE Industrial Bhd
KLSE:7095
|
0.036x |
|
Namsun Alumini
KO:008350
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Photocure (2002–2024)
The table below shows the annual cash flow conversion efficiency of Photocure from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Photocure market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr501.72 Million ≈ $52.79 Million |
Nkr76.75 Million ≈ $8.08 Million |
0.153x | +151.36% |
| 2023-12-31 | Nkr482.85 Million ≈ $50.81 Million |
Nkr29.39 Million ≈ $3.09 Million |
0.061x | +1495.53% |
| 2022-12-31 | Nkr462.73 Million ≈ $48.69 Million |
Nkr-2.02 Million ≈ $-212.35K |
-0.004x | -109.18% |
| 2021-12-31 | Nkr502.63 Million ≈ $52.89 Million |
Nkr23.89 Million ≈ $2.51 Million |
0.048x | +54.94% |
| 2020-12-31 | Nkr508.13 Million ≈ $53.47 Million |
Nkr15.59 Million ≈ $1.64 Million |
0.031x | -69.03% |
| 2019-12-31 | Nkr208.59 Million ≈ $21.95 Million |
Nkr20.66 Million ≈ $2.17 Million |
0.099x | +172.38% |
| 2018-12-31 | Nkr176.34 Million ≈ $18.56 Million |
Nkr-24.12 Million ≈ $-2.54 Million |
-0.137x | -26.45% |
| 2017-12-31 | Nkr218.08 Million ≈ $22.95 Million |
Nkr-23.59 Million ≈ $-2.48 Million |
-0.108x | -242.01% |
| 2016-12-31 | Nkr251.94 Million ≈ $26.51 Million |
Nkr19.19 Million ≈ $2.02 Million |
0.076x | +176.09% |
| 2015-12-31 | Nkr210.06 Million ≈ $22.10 Million |
Nkr-21.03 Million ≈ $-2.21 Million |
-0.100x | -294.80% |
| 2014-12-31 | Nkr240.06 Million ≈ $25.26 Million |
Nkr-6.09 Million ≈ $-640.63K |
-0.025x | +93.16% |
| 2013-12-31 | Nkr269.12 Million ≈ $28.32 Million |
Nkr-99.72 Million ≈ $-10.49 Million |
-0.371x | -156.53% |
| 2012-12-31 | Nkr380.27 Million ≈ $40.02 Million |
Nkr-54.93 Million ≈ $-5.78 Million |
-0.144x | -84.12% |
| 2011-12-31 | Nkr439.34 Million ≈ $46.23 Million |
Nkr-34.47 Million ≈ $-3.63 Million |
-0.078x | -330.80% |
| 2010-12-31 | Nkr458.85 Million ≈ $48.28 Million |
Nkr15.60 Million ≈ $1.64 Million |
0.034x | -95.55% |
| 2009-12-31 | Nkr415.78 Million ≈ $43.75 Million |
Nkr317.44 Million ≈ $33.40 Million |
0.763x | +355.48% |
| 2008-12-31 | Nkr199.69 Million ≈ $21.01 Million |
Nkr-59.68 Million ≈ $-6.28 Million |
-0.299x | +18.77% |
| 2007-12-31 | Nkr259.99 Million ≈ $27.36 Million |
Nkr-95.66 Million ≈ $-10.07 Million |
-0.368x | -281.35% |
| 2006-12-31 | Nkr326.94 Million ≈ $34.40 Million |
Nkr66.33 Million ≈ $6.98 Million |
0.203x | +113.94% |
| 2005-12-31 | Nkr48.47 Million ≈ $5.10 Million |
Nkr-70.54 Million ≈ $-7.42 Million |
-1.455x | -147.85% |
| 2004-12-31 | Nkr85.57 Million ≈ $9.00 Million |
Nkr-50.25 Million ≈ $-5.29 Million |
-0.587x | -9.86% |
| 2003-12-31 | Nkr131.90 Million ≈ $13.88 Million |
Nkr-70.51 Million ≈ $-7.42 Million |
-0.535x | -75.36% |
| 2002-12-31 | Nkr167.00 Million ≈ $17.57 Million |
Nkr-50.91 Million ≈ $-5.36 Million |
-0.305x | -- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more